Test - Ascendis Pharma

NEWS RELEASES

April 8, 2026

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

April 6, 2026

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

March 17, 2026

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

Phase 1

Phase 2

Phase 3

TransCon hGH

Pediatric growth hormone deficiency2

test

Phase 2

test

Adult growth hormone deficiency

Phase 2

TransCon PTH

Adult hypoparathyroidism

Phase 3

Phase 1

Phase 2

Phase 3

sss

Phase 2

sdsd

sss

Phase 3

sss

sds

You are about to access www.ascendispharma.com.
Click below if you wish to proceed.

GO CANCEL

Sie verlassen nun die Ascendis Pharma-Webseite und werden auf eine externe Webseite weitergeleitet. Ascendis Pharma übernimmt keine Verantwortung für den Inhalt auf der externen Webseite.

WEITER ABBRECHEN